Buscar
Talphera Inc
TLPHAñadir a la lista de seguimiento
1.305USD
+0.045+3.57%
Cierre 07-28 16:00（ET）Cotizaciones retrasadas 15 min
65.32MCap. mercado
PérdidaP/E TTM
Más Datos de Talphera Inc Compañía
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Información de Talphera Inc
Símbolo de cotizaciónTLPH
Nombre de la empresaTalphera Inc
Fecha de salida a bolsaFeb 11, 2011
Director ejecutivoAngotti (Vincent J)
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 11
Dirección1850 Gateway Drive
CiudadSAN MATEO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94404
Teléfono16502163500
Sitio Webhttps://talphera.com/
Símbolo de cotizaciónTLPH
Fecha de salida a bolsaFeb 11, 2011
Director ejecutivoAngotti (Vincent J)
Ejecutivos de Talphera Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
45.03K
-5.43%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
20.87K
-21.65%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
18.44K
+27.65%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Director
Director
11.50K
+44.36%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
9.69K
+52.62%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Independent Director
Independent Director
7.85K
+64.94%
Dr. Stephen J. Hoffman, M.D., Ph.D.
Dr. Stephen J. Hoffman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Vincent J. (Vince) Angotti
Mr. Vincent J. (Vince) Angotti
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
45.03K
-5.43%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
20.87K
-21.65%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
18.44K
+27.65%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Director
Director
11.50K
+44.36%
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
9.69K
+52.62%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Independent Director
Independent Director
7.85K
+64.94%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Talphera Inc?
Los cinco principales accionistas de Talphera Inc son: Mr. Badri N. Dasu
¿Cuántas instituciones poseen acciones de Talphera Inc (TLPH)?
A fecha de 2026Q1, 68 instituciones poseen acciones de Talphera Inc, con un valor de mercado combinado de aproximadamente 20.36M, lo que representa el 40.00% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 746542.00.
¿Cuál es la mayor fuente de ganancias de Talphera Inc?
El 2026Q1, el segmento empresarial DSUVIA generó la ganancia más alta para Talphera Inc, ascendiendo a 1.59M y representando el 89.67% de la ganancia total.